title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
1. Introduction | ill | RECRUITMENT | The author (Barbara D’Amen) carried out the project activities and contributed to the writing of the article as a researcher at the Centre for Socio-Economic Research on Ageing, National Institute of Health and Science on Ageing (IRCCS INRCA). Since 15 January 2023, she has been a researcher at the Italian National Ins... | PMC10049644 |
2. Materials and Methods | The ME-WE project included a wide range of quantitative and qualitative research, co-design and knowledge translation activities dealing with the phenomenon of AYCs in Europe. Below, we describe, review and critique the methods and recruitment-related aspects of the trial evaluating the newly designed psychosocial inte... | PMC10049644 | ||
2.1. Design | The ME-WE psychosocial intervention was designed as a cluster-randomised controlled trial (C-RCT) design, with a two (arm) by three (times) repeated measures factorial design [Clusters consisted of AYCs attending the same school (in Slovenia, Sweden and Switzerland) or living in the same geographical area (e.g., neighb... | PMC10049644 | ||
2.2. Intervention | activity/ies | SESSION | The ME-WE primary prevention intervention was developed by refining the existing DNA-V protocol [Participants of clusters allocated to the ME-WE intervention arm attended seven weekly 2 h group sessions, with a follow-up meeting after 3 months from the end of the intervention. Groups were comprised of 2 to 9 AYCs (with... | PMC10049644 |
2.3. Ethics Approval and Informed Consent | The study protocol and related documentation were assessed and approved/expert opinions were provided (in accordance with national legislation) by competent ethics committees in each of the six countries during 2019. All participants were engaged in the study on a voluntary basis in accordance with the Declaration of H... | PMC10049644 | ||
2.4. Sample | During the study protocol preparation, we conducted an average sample size estimation for each country (considering the cluster-level randomisation) [The minimum total sample sizes obtained from this procedure were as follows ( | PMC10049644 | ||
2.5. Inclusion and Exclusion Criteria | a disability | RECRUITMENT | To be eligible for the study, the following inclusion criteria were established: (1) aged between 15 and 17 years at the recruitment stage; (2) caring for family member(s) (e.g., parents, siblings, grandparents) or significant other(s) (e.g., friends, schoolmates or neighbours) with a disability, chronic physical and/o... | PMC10049644 |
2.6. Compassionate Cases | RECRUITMENT | All participating countries allowed participants who did not meet the inclusion criteria to attend the ME-WE groups. They were identified as AYCs during recruitment and were interested in participating in the intervention. They expressed a need for support, but no alternatives for support other than the ME-WE-groups we... | PMC10049644 | |
2.7. Recruitment | RECRUITMENT | The recruitment of AYCs was carried out between April 2019 and September 2020. All countries employed cluster-targeted recruitment methods aimed to reach a convenience sample. The efforts were invested to overcome the known difficulties to reach and involve AYCs, especially in countries where there is no formal recogni... | PMC10049644 | |
2.8. Adaptation of Study Protocols | The COVID-19 pandemic posed (from March 2020 onwards) considerable challenges to the trial study in all six countries. Largely due to ethical considerations put forward by the project’s International Advisory and Ethics Board (IAEB), namely the possibility to continue to offer support to AYCs during the pandemic via th... | PMC10049644 | ||
2.9. CONSORT Flowchart | The Consolidated Standard of Reporting Trials (CONSORT) 2010 statement extended to cluster trials was followed in this study [ | PMC10049644 | ||
3. Results | PMC10049644 | |||
3.1. Recruitment Process in the Six Countries | RECRUITMENT | There were considerable difficulties in recruiting AYCs to the trial. Below, we present a summary of recruitment efforts and outcomes for each country. | PMC10049644 | |
3.1.1. Italy | RECRUITMENT | Initially, in Italy, researchers attempted to recruit AYCs in high schools and municipalities but without success, due to the low level of visibility of AYCs. Thus, it was decided to try to engage AYCs with the mediation of public or private health and/or social care services and through condition-specific associations... | PMC10049644 | |
3.1.2. The Netherlands | RECRUITMENT | In the Netherlands, the recruitment was carried out through schools and care support centres. The first wave of recruitment involved the following: (a) A total of nine schools (three high schools and six schools in vocational education) entered the study, of which six schools in vocational education cancelled participa... | PMC10049644 | |
3.1.3. Slovenia | disability | RECRUITMENT | In Slovenia, the recruitment strategy was built on liaising with high schools as well as with non-governmental organisations and care services dedicated to the disability and mental health fields concerning young people and adults. The majority of the recruitment was carried out via school presentations and direct recr... | PMC10049644 |
3.1.4. Sweden | RECRUITMENT | In Sweden, a school campaign was conducted, which reached out to 1081 students and 354 school staff in twelve schools. In the first intervention wave, Sweden adopted a blended delivery approach. In the second wave, with COVID-19 restrictions underway, all recruitment was conducted via advertisements and videos on socia... | PMC10049644 | |
3.1.5. Switzerland | RECRUITMENT, RECRUITMENT | In Switzerland, recruitment was initially entirely and directly through schools. Recruitment was expanded in December 2019, and whilst it continued through the schools (with additional direct recruitment on school campuses), recruitment also took place through a wider range of additional stakeholders from the health an... | PMC10049644 | |
3.1.6. United Kingdom | STRUCK, RECRUITMENT | In the UK, there were two waves of recruitment. In the first wave, Carers Trust (a UK-based charity) led the recruitment of the young carers projects to the study through its network of young carers support services. Carers Trust sent out informational leaflets to its network of hundreds of young carers projects across... | PMC10049644 | |
3.2. Recruitment Results | RECRUITMENT | There were considerable differences in recruitment outcomes across countries. A large number of screen failures (young people who, among those screened, did not match with the screening criteria) are noted in the Netherlands and Slovenia, and these countries, together with Sweden, also recorded a prominent number of wi... | PMC10049644 | |
3.3. Target Sample Size vs. Final Sample Size: Challenges | RECRUITMENT | Due to difficulties in the recruitment process, recruitment to the control groups was often delayed and thus they contain a smaller number of AYCs than the intervention group/s. Additionally, the amount of reported data from the control groups differs between the countries, making a comparison more difficult. As can be... | PMC10049644 | |
3.4. Mitigation Measures Implemented | RECRUITMENT | Project partners implemented several measures along the recruitment process, aimed at mitigating the abovementioned challenges and the risk of involving too few participants: Extra efforts in communication activities: All partners implemented additional communication activities to reach-out to a larger number of potent... | PMC10049644 | |
4. Discussion | RECRUITMENT | The recruitment of participants for the ME-WE trial study has certainly proved that AYCs are a hard-to-reach target group for researchers and practitioners. A lower number of participants were recruited and fully engaged, despite the significant recruitment efforts that were made and additional efforts spent. In order ... | PMC10049644 | |
5. Conclusions | influencer, ’ interests | EVENT, RECRUITMENT | Drawing from the lessons learned from the recruitment process in our study and inputs received by stakeholders during the project (the IAEB and the Eurocarers Young Carers Working Group), we developed a set of recommendations and practical suggestions for researchers and practitioners dealing with AYCs, which may help ... | PMC10049644 |
Author Contributions | Conceptualisation, E.H., L.M., F.B., L.B., G.C. and V.H.; methodology, G.C., L.B., E.H., L.M. and V.H.; validation, G.C., L.B., E.H., L.M. and V.H.; formal analysis, E.H., L.M., F.B., L.B., G.C. and V.H.; investigation, E.H., L.B., G.C., V.H., I.B., F.L., R.H., R.B., S.S., M.S., B.D., Y.d.J., T.B., N.d.J., A.L., D.P., ... | PMC10049644 | ||
Institutional Review Board Statement | This study was conducted in accordance with the Declaration of Helsinki. Formal ethics approvals (and amendments, due to COVID-19 insurgence) were obtained from the ethical review boards of the University of Bologna (Italy) (116994; 144521), University of Ljubljana (Slovenia) (20 August 2019; 20 April 2020; 20 August 2... | PMC10049644 | ||
Informed Consent Statement | Written informed consent was obtained from all subjects involved in the clinical study. | PMC10049644 | ||
Data Availability Statement | The ME-WE project reports, deliverables and outputs are publicly accessible in the project website: | PMC10049644 | ||
Conflicts of Interest | The authors declare no conflict of interest. | PMC10049644 | ||
References | RECRUITMENT | CONSORT flow diagram for the original study protocol.Minimum composition of the national sample size (initial estimation).Recruitment of participants to the ME-WE trial for each partner country.* Total number of young persons who applied to the study and were screened. This number includes participants with informed co... | PMC10049644 | |
Background | BTV | Mechanical ventilation during general anesthesia may impair airway mucosal function. This study aimed to investigate the effect of pressure-controlled ventilation-volume guaranteed (PCV-VG) on bronchial mucus transport velocity (BTV) in patients during laparoscopic surgery for gynecological oncology compared with volum... | PMC10658982 | |
Methods | PNEUMOPERITONEUM | 66 patients undergoing elective a laparoscopic surgery for gynecological oncology. The patients were randomized into two group receiving either PCV-VG or VCV. a drop of methylene blue was placed on the surface of the airway mucosa under the bronchoscopeand, then the distance the dye movement was measured after 2, 4, an... | PMC10658982 | |
Results | 64 patients were included in the analysis. The median [interquartile range] BTV was significantly lower in VCV group at T1 and T2 that at T0 ( | PMC10658982 | ||
Conclusions | PCV-VG | PCV-VG is more suitable for patients undergoing laparoscopic surgery for gynecological oncology than VCV since it can protect mucociliary clearance function. | PMC10658982 | |
Trial registration | This trial is registered on | PMC10658982 | ||
Keywords | PMC10658982 | |||
Background | Airway mucosa is the most important natural defense system in the body and is considered the first line of defense of the respiratory system [Pressure-controlled ventilation-volume guaranteed (PCV-VG) mode utilizes a decelerating flow and constant pressure to achieve volume control and pressure control. It has thus bee... | PMC10658982 | ||
Methods | PMC10658982 | |||
Study design | This was a single-center, prospective, patient and observer-blinded, randomized- controlled trial. This study was reported following the CONSORT reporting guidelines [ | PMC10658982 | ||
Study population | atopy, tumor | RESPIRATORY DISEASE, MAY, TUMOR, ATOPY | First, all patients scheduled to undergo elective laparoscopic gynecologic tumor resection at the First Affiliated Hospital of Medical College, Shihezi University, China, from 12 October 2022 to 13 May 2023, were recruited. Next, only patients aged 40–75 years and met the American Society of Anesthesiologists’ (ASA) ph... | PMC10658982 |
Anesthesia procedures | patients-Dash | MUSCLE RELAXATION | The patients were not administered preoperative medications. Electrocardiogram, pulse oximetry, non-invasive blood pressure, and Bispectral Index Sensor (BIS, Aspect Medical Systems, Newton, MA, USA) were used to monitor all patients-Dash 3000 monitor, GE Company, Madison, USA. Anesthesia was induced using a bolus cont... | PMC10658982 |
Study intervention | PNEUMOPERITONEUM | The patients received ventilation using the same type of Anesthesia Machine (Datex-Ohmeda-Avance CS2, GE Company, Madison, USA) after induction of anesthesia and intubation. Anesthesia machine parameters were similar under the two modes (VT; 8 ml /kg, inspiratory/expiratory ratio (I/E); 1:2, positive end-expiratory pre... | PMC10658982 | |
Measurements | BTV | SECONDARY, PNEUMOPERITONEUM | The respiratory circuit was disconnected at T0, T1, and T2 time points as described by Seo H and Kim SH et al. [Method for measuring bronchial mucus transport velocity (BTV). Data were collected at the following time points:Baseline; 5 min after endotracheal intubation and before initiation of the pneumoperitoneum (T0)... | PMC10658982 |
Sample size | PASS 15 Power Analysis and Sample Size Software (2017NCSS, LLC. Kaysville, Utah, USA) was used to determine the minimum number of samples. For BTV, a minimum number of 16 patients per group was required to detect a difference of at least 5.0 mm/min with a two-tailed alpha error of 0.05 and desired power of 80% (accordi... | PMC10658982 | ||
Randomization and blinding | PCV-VG | The 66 subjects were divided into two groups (1:1) using SPSS 26.0 software program (IBM SPSS Statistics, Chicago, Illinois, USA). and computer random number method. 33 pairs of numbers (1 or 2) were randomly generated, where 1 and 2 corresponded to the PCV-VG and VCV groups, respectively. The intervention methods adop... | PMC10658982 | |
Statistical analyses | cancer | CANCER, PNEUMOPERITONEUM | Normal distribution of data was assessed using the Shapiro-Wilktest test. The equality of group variances was evaluated using the homogeneity of variance test (Levene statistic). Two independent samples t-tests were used to analyze data for age, height, BMI, weight, anesthesia time, pneumoperitoneum time, forced expira... | PMC10658982 |
Discussion | BTV, throat | PNEUMOPERITONEUM | In this study, both VCV and PCV-VG ventilation modes inhibited BTV in patients during laparoscopic surgery for gynecological oncology, and the degree of inhibition increased with increasing pneumoperitoneum time. The degree of BTV inhibition was not significantly different between the two groups at 1 h after pneumoperi... | PMC10658982 |
Acknowledgements | We would like to express our sincere gratitude to all the participants for theirsupport and contribution to this research. We greatly appreciate the assistancefrom all the surgical and operating room members of First Affiliated Hospital, Shihezi University for their support in conducting this study. | PMC10658982 | ||
Authors’ contributions | Chao Deng and Tao Xu developed the concept and drafted the manuscript; Chao Deng and XK Wang performed the experiments and data acquisition; DF Gu contributed to the literature research and data analysis; T Xu revised the manuscript. All have read the final version of this paper and have agreed with this submission. | PMC10658982 | ||
Funding | This research was conducted with financial support from a research scholarship supported though funding from Science and Technology Bureau (No.2022ZD037). | PMC10658982 | ||
Availability of data and materials | The datasets used and analyzed during the current study are available from the corresponding author on request. | PMC10658982 | ||
Declarations | PMC10658982 | |||
Ethics approval and consent to participate | This study was approved by the Research Ethics Board of The First Affiliated Hospital of Shihezi University School of Medicine (Shihezi, China) and is registered on | PMC10658982 | ||
Consent for publication | Not applicable. | PMC10658982 | ||
Competing interests | The authors declare no competing interests. | PMC10658982 | ||
References | PMC10658982 | |||
Abstract | PMC10109340 | |||
Objective | MULTIPLE SCLEROSIS (MS) | This study aimed to evaluate safety (infusion‐related reactions [IRRs]) and patient satisfaction (patient‐reported outcomes [PROs]) for at‐home ocrelizumab administration for patients with multiple sclerosis (MS). | PMC10109340 | |
Methods | ADVERSE EVENTS, DISEASE | This open‐label study included adult patients with an MS diagnosis who had completed a ≥ 600‐mg ocrelizumab dose, had a patient‐determined disease steps score of 0 to 6 and had completed PROs. Eligible patients received a 600‐mg ocrelizumab home‐based infusion over 2 h, followed by 24‐h and 2‐week post‐infusion follow‐... | PMC10109340 | |
Results | fatigue, grogginess, itch, mild/moderate | Overall, 99 of 100 expected patients were included (mean [SD] age, 42.3 [7.7] years; 72.7% female; 91.9% White). The mean (SD) infusion time was 2.5 (0.6) hours, and 75.8% of patients completed their ocrelizumab infusion between 2 to 2.5 h. The IRR incidence rate was 25.3% (95% CI: 16.7%, 33.8%)—similar to other shorte... | PMC10109340 | |
Interpretation | IRRs and AEs occurred at acceptable rates during in‐home infusions of ocrelizumab over a shorter infusion time. Patients reported increased confidence and comfort with the home infusion process. Findings from this study provide evidence of the safety and feasibility of home‐based ocrelizumab infusion over a shorter inf... | PMC10109340 | ||
Introduction | MULTIPLE SCLEROSIS (MS), DISEASE | Treatment for multiple sclerosis (MS) often requires routine and long‐term care for optimal disease management, including the administration of disease‐modifying therapies (DMTs) by intravenous (IV) infusion.Ocrelizumab is a recombinant, humanized monoclonal antibody that selectively targets CD20‐expressing B cells and... | PMC10109340 | |
Methods | PMC10109340 | |||
Trial design | ADVERSE EVENT, RECRUITMENT | This was an open‐label, single‐arm, nonrandomized study to evaluate the safety and patient experience of ocrelizumab infusion over a 2‐h period via home‐based infusion (NCT04650321). The similarly designed Phase IIIb, open‐label SaROD study of accelerated ocrelizumab infusions was used as a historical control.Eligible ... | PMC10109340 | |
Patient population | In this study, participant selection was designed to reflect real‐world patients with MS who receive ocrelizumab. Enrollment occurred on a rolling basis over a 12‐month period from active patients of the Rocky Mountain MS Center (RMMSC) at the University of Colorado Anschutz Medical Campus until the target population o... | PMC10109340 | ||
Outcome measures | Cancer | ADVERSE EVENT, DISEASE, DISEASE CHARACTERISTIC, APPENDIX, CANCER | Data collected at screening and pre‐infusion visits consisted of patient demographics (age, sex, race, and ethnicity) and clinical disease characteristics (type of MS, disease duration, DMT type, DMT duration, PDDS score, and number of prior ocrelizumab infusions). Infusion procedure variables documented during the inf... | PMC10109340 |
Statistical analysis | DISEASE CHARACTERISTIC | Descriptive statistics were used to summarize patient demographics, clinical disease characteristics, infusion procedure variables and AEs for the ITT population. Controls were limited to available historic data from the SaROD study.The frequencies and proportions of IRRs for the primary outcome were summarized descrip... | PMC10109340 | |
Results | PMC10109340 | |||
Patient demographics and disease characteristics | RRMS | DISEASE, MULTIPLE SCLEROSIS, DISEASE CHARACTERISTIC | Between August 2020 and February 2021 medical charts were reviewed for 925 eligible patients with MS, and 312 patients were contacted by the study team (Fig. Patient identification and attrition.A total of 99 patients with MS were included in the ITT population in this home infusion cohort study. The mean (SD, range) a... | PMC10109340 |
Summary of at‐home ocrelizumab infusion procedures | The majority of patients received acetaminophen (94.9%), methylprednisolone (89.9%) and diphenhydramine (88.9%) prior to their ocrelizumab infusion (Table Infusion procedure by study cohort.One patient switched to 25 mg of diphenhydramine due to a prior reaction with the 50‐mg dose.Longer infusion times may have been a... | PMC10109340 | ||
Overall, only 25.3% (95% CI: 16.7%, 33.8%) of patients experienced an IRR of any grade during the at‐home ocrelizumab infusion. These IRRs were 18.2% Grade 1 (95% CI: 10.6%, 25.8%) and 7.1% Grade 2 (95% CI: 2.9%, 14.0%); no IRRs were classified as ≥Grade 3 (95% CI: 0.0%, 3.7%) (Fig. Frequency of infusion‐related reacti... | PMC10109340 | |||
Patient‐reported | ADVERSE EVENT | Among these patients, a total of 174 AEs were reported, and 66.7% of patients experienced an AE with at‐home ocrelizumab infusion (Fig. Post‐infusion (A) patient‐reported AEs and (B) most common patient‐reported AEs. AE, adverse event; GI gastrointestinal. | PMC10109340 | |
Patient experience with home‐based ocrelizumab treatment | Patients reported favorable scores across PRO measures of their at‐home infusion experience, compared to their prior infusion experience at an infusion center. Significant improvements from were reported following a home for overall experience with the at‐home infusion process (The (A) overall patient experience with o... | PMC10109340 | ||
Discussion | DISEASE, RECRUITMENT | This open‐label, single‐arm, nonrandomized study is among the first to assess the safety of the at‐home infusion of ocrelizumab. Leveraging the shorter infusion regimen, at‐home administration did not increase the incidence of IRRs compared with the SaROD trial of the shorter infusion protocol for administering ocreliz... | PMC10109340 | |
Author Contributions | PMC10109340 | |||
Conflict of Interest Statement | PMC10109340 | |||
Funding Information | INTERACTIONS | NIH funding was provided by CTSA grants UL1 TR002535, KL2 TR002534, and TLI TR002533. This study was sponsored by F. Hoffmann‐La Roche Ltd and Genentech, Inc. Support for third‐party writing assistance, furnished by Charli Dominguez, PhD, CMPP, of Health Interactions, Inc, was provided by F. Hoffmann‐La Roche Ltd. | PMC10109340 | |
Supporting information |
Click here for additional data file. | PMC10109340 | ||
Acknowledgements | We thank the patients and their families who participated in this study. We also acknowledge the Adult Clinical and Translational Research Center (CTRC) Nursing services at the Colorado Clinical and Translational Sciences Institute (CCTSI). | PMC10109340 | ||
Data Availability Statement | The datasets generated and/or analyzed during the current study are not publicly available as this study involved the merging of data from several different sources (patient‐reported outcomes, laboratory outcomes, telehealth visit data) and different electronic systems (home infusion center, academic medical center) bu... | PMC10109340 | ||
References | PMC10109340 | |||
Background | Cell salvage reduces allogenic blood transfusion requirements in surgery. We present a pilot study exploring the impact of anticoagulant choice, citrate or heparin, on the quality of cell salvaged blood in adults undergoing coronary artery bypass grafting (CABG). | PMC10082980 | ||
Materials and methods | inflammation | INFLAMMATION | Elective on pump CABG patients were randomly allocated to citrate or heparin anticoagulation. We measured red blood cell characteristics and inflammation in both the blood collection reservoir and the washed red blood cell concentrate. Postoperatively, the level of biomarkers and the coagulation profile in the peripher... | PMC10082980 |
Results | Thirty eight patients were included, 19 in the citrate group and 19 in the heparin group. Baseline characteristics were similar. In the washed red blood cell concentrate, Mean Hb (g/dl) and Ht (%) were lower in the citrate group [Hb: 18.1 g/dL (SD 1.3) vs. 21.1 (1.6), | PMC10082980 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s13019-023-02246-w. | PMC10082980 | ||
Keywords | PMC10082980 | |||
Background | blood loss | BLOOD LOSS, ADVERSE EFFECTS, BLOOD | Allogenic blood transfusion, a necessary tool in managing perioperative blood loss, has several adverse effects. Perioperative allogenic blood transfusion, even when limited in volume, is associated with postoperative morbidity, increased length of stay and so cost, and mortality in both general and cardiac surgery [Bl... | PMC10082980 |
Methods | intraoperative bleeding, blood loss, neoplasia, infection, hemolysis | BLOOD LOSS, NEOPLASIA, CHRONIC INFLAMMATORY DISEASE, INFECTION, BLOOD, HEMOLYSIS, INTRAOPERATIVE BLEEDING | This single center pilot study (NCT02674906) was performed in the operating room and the mixed medical-surgical ICU of Ziekenhuis Oost Limburg (ZOL), Genk, Belgium, a 805-bed non-university teaching hospital. This study was approved by the local ethics committee and written informed consent was obtained prior to surger... | PMC10082980 |
Results | Over a 3 month study period, a total of 38 patients were included, 19 patients in each group. There were no significant differences in baseline characteristics, including fasting lipid profiles, between the groups, apart from a higher lymphocyte count in the citrate exposed patients (of citrate group) (Table Panel A. B... | PMC10082980 | ||
The quality of WRBC | WRBC from patients in the citrate group had lower Hb, Ht and RBC count compared to heparin exposed patients (Table WBC counts did not differ between groups in WRBC. WBC differentiation showed a higher count and percentage for lymphocytes, monocytes and eosinophils in the citrate group (see Table | PMC10082980 | ||
Inflammatory parameters | In the BCR, despite no difference at baseline, the anti-inflammatory marker IL-10 was significantly higher in the citrate group [203.70 (108.98–411.42) vs 108.10 (60.00–176.71) Before WRBC transfusion, there were no significant differences in inflammatory parameters between the groups (see Additional file Results in pa... | PMC10082980 | ||
The impact after transfusion of WRBC | Free Hb, iron, ferritin, haptoglobin and hepcidin did not differ between the groups, both before and after WRBC transfusion. There was no difference in aPTT, PT, INR and ROTEM analysis before and after WRBC transfusion between groups. Both intra-operatively and post-operatively there was no difference between the group... | PMC10082980 | ||
Cell salvage volumes | There were no significant differences between study groups in total fluid volume collected in BCR, ATBR, incubation time, waste fluid and washing fluid. Although the volume of WRBC was higher in the citrate group this difference was not significant. The significant difference in Ht in WRBC between groups (see Table No ... | PMC10082980 | ||
Discussion | blood loss, hemolysis, postoperative bleeding | HYPOTONIC, BLOOD LOSS, POSTOPERATIVE BLEEDING, FRAGILITY, BLOOD, HEMOLYSIS, INFLAMMATORY RESPONSE | In this trial comparing the effects of differing anticoagulant regimens (citrate or heparin) on cell salvage in adult patients undergoing elective pump CABG, small but relevant differences were observed between the two groups. WRBC had a significantly lower hematocrit and higher MCV and a larger residual thrombocyte co... | PMC10082980 |
Conclusion | BLOOD, RESIDUAL | This study comparing citrate vs. heparin in cell salvage in adults undergoing coronary artery bypass grafting (CABG) found significant differences in the washed red blood cell concentrates: Hb and Hct were lower in the citrate group and the washed red blood cells had a higher MCV and lower MCHC. Residual trombocyte cou... | PMC10082980 | |
Author contributions | MVT | WB: Conception and design of the study; the acquisition of data and data analysis, interpretation of data; drafting of and substantive revision of the manuscript. MVT: Design of study, the acquisition of data and data analysis; drafting of and substantive revision of the manuscript. MB: Design of study, the acquisition... | PMC10082980 | |
Funding | None. | PMC10082980 | ||
Availability of data and materials | The datasets during and/or analysed during the current study available from the corresponding author on reasonable request. | PMC10082980 | ||
Declarations | PMC10082980 | |||
Ethics approval and consent to participate | The study protocol was approved by the local institutional review board (Commissie Medische Ethiek, Ziekenhuis Oost‐Limburg, approval. Written informed consent to participate in the study was obtained prior to surgery from the patient or legal representative. | PMC10082980 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.